Abstracts

261 – Plasma Metabolomics Uncover Multiple Dysregulations Indicating Gut Damage in SIV-Infected Macaques

Background Despite effective antiretroviral therapies (ART), people living with HIV (PWH) have elevated rates of inflammation, hypercoagulation, and associated comorbidities. Gut damage correlates with immune dysfunction in PWH, but precise etiologies remain poorly defined. Due to heterogeneity of clinical cohorts, generalizable metabolomic studies from PWH are limited but can be augmented with animal models. Methods…

263 – Productive HIV-1 Infection in CRISPR CD4/CCR5/C1qbp Knock-In CD8-Depleted Mice

Background Rodents cannot be infected with HIV due to multiple obstacles. First, HIV requires human CD4/CCR5/CXCR4 on human immunocytes, each are structured differently in mice. Second, post-transcriptional factors absent in rodent cells limit viral RNA export, translation, stability, viral assembly, and release.  Third, rodent CD8+ T-cell viral control is active in rodents with active killing of…

273 – PD-1 Expression on PBMCs in PLHIV Mainly Influences CD4+-Lymphocyte Functionality

Background Anti-PD-1 immunotherapy (API) could reverse T-cell exhaustion, strengthen HIV-specific T-cell responses, and reduce the HIV reservoir in people living with HIV (PLHIV). However, API responsiveness does not directly correlate with PD-1 expression on T-cells, suggesting that receptor heterogeneity may influence therapeutic outcomes. This study aimed to assess: 1) the variation of PD-1 expression among…

277 – The Microbiome of Exceptional Elite Controllers Linked to HIV-Specific Immune Responses

Background Elite Controllers (EC) are a model for HIV cure research, maintaining durable viral suppression without ART through unique immune responses. The microbiome could regulate HIV-specific responses in EEC by affecting inflammation and antiviral immunity. Methods We established a cohort of exceptional EC (EEC, >10 years HIV control without ART, VL <50 copies/mL, CD4 nadir…

566 – Successful Use of B/F/TAF in PWH With nRTI Resistance Including Multiple TAMs and K65R/N Mutations

Background Bictegravir/emtricitabine/tenofovir alafenamide (BFTAF) is an efficacious and preferable regimen in many contexts, but experience of its use in people with pre-existing HIV-1 nucleoside reverse transcriptase inhibitor (NRTI) resistance-associated mutations (RAMs) beyond M184V remains limited. TAF is thought to exert higher activity against virus with tenofovir mutations owing to high intracellular concentration, suggesting potential utility…

573 – Resistance Mutations in Intact vs Defective HIV Proviruses: Implications for Proviral DNA Testing

Background HIV proviral DNA drug resistance testing has not consistently predicted treatment outcomes, yet it may be valuable for regimen optimization during virologic suppression. Because only genome-intact proviruses drive viral rebound, resistance confined to defective, non-hypermutated genomes may have limited clinical relevance, but they remain included in commercial DNA drug resistance testing. We analyzed near-full-length…

580 – From Widespread Use to Salvage Therapy: Seventeen Years of Protease Inhibitor Resistance Dynamics

Background The use of protease inhibitors (PIs) has played a central role in antiretroviral (ARV) therapy, but has also driven the emergence of specific resistance mutation patterns. Over time, the PI class has evolved from first-generation drugs such as indinavir (IDV), saquinavir (SQV), nelfinavir (NFV) and amprenavir (APV), to more robust and better tolerated agents…

856 – Clinical and Cost Impact of Long-Acting ART in South African Youth With HIV: A Modeling Analysis

Background Youth with HIV (YHIV) aged 15-24 years in South Africa (SA) experience challenges adhering to daily oral antiretroviral therapy (ART) compared to older people with HIV, leading to substantial short- and long-term morbidity and mortality. Long-acting injectable cabotegravir/rilpivirine (CAB/RPV) could reduce adherence barriers but is not available for treatment outside research settings.  Methods Using…

1056 – Some Barriers Persist, But State AIDS Drug Assistance Programs’ Challenges Ease Overall: 2017-2023 

Background AIDS Drug Assistance Programs (ADAPs) provide access to antiretroviral therapy for people with HIV with low incomes. Longitudinal trends in the challenges that ADAPs navigate have not been evaluated. Given recent policy shifts, such as the end of Medicaid continuous coverage, rising prescription drug and insurance costs, and federal funding uncertainty, we examined trends…